Cancer Research Cancer Epigenetics  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 4073-4078, September 15, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doroshow, J. H.
Right arrow Articles by Kane, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doroshow, J. H.
Right arrow Articles by Kane, S. E.

Transduction of NIH 3T3 Cells with a Retrovirus Carrying Both Human MDR1 and Glutathione S-Transferase {pi} Produces Broad-Range Multidrug Resistance1

James H. Doroshow, Marianne Z. Metz, Linda Matsumoto, Katherine A. Winters, Masaharu Sakai, Masami Muramatsu and Susan E. Kane2

Departments of Medical Oncology and Therapeutics Research [J. H. D., L. M., K. A. W.] and Cell and Tumor Biology [M. Z. M., S. E. K.], City of Hope National Medical Center, Duarte, California 91010; Department of Biochemistry, Hokkaido University School of Medicine, N15, W7, Sapporo 060, Japan [M. S.]; and Department of Biochemistry, Saitama Medical School, 38 Morohongo, Moroyama, Iruma-gun 350-04, Saitama, Japan [M. M.]

In these experiments, we examined the ability of a retroviral vector, pHaMASV, to encode two potential chemoprotective genes on separate transcription units. We previously described the pHaMSV vector, which includes the human MDR1 gene as a selectable marker and chemoprotective gene, plus an internal SV40 promoter for expressing a second heterologous gene along with MDR1 [M. E. Metz, D. M. Best, and S. E. Kane. Virology, 208: 634–643, 1995]. To test the ability of this vector to deliver two therapeutic genes simultaneously, the cDNA for human glutathione S-transferase {pi} (GST {pi}, the most abundant member of the glutathione S-transferase family in human tumor cells) was inserted into pHaMASV, and this plasmid was transfected into ecotropic packaging cells. The resulting pHaMASV.GST {pi} ecotropic retrovirus, which was produced at a titer of 2 x 106 colony-forming units/ml, was used to transduce NIH 3T3 cells. After initial selection in 60 ng/ml colchicine, a population of transduced cells was exposed to stepwise increasing colchicine concentrations to select for amplified expression of MDR1. As MDR1 expression increased, the expression of GST {pi} increased in concert, as demonstrated by Northern analysis, Western analysis, and measurements of glutathione S-transferase activity. Transduced cells growing in 1280 ng/ml colchicine had about 3-fold higher total glutathione S-transferase activity than nontransduced cells and 2.5-fold higher activity than transduced cells growing in 60 ng/ml colchicine. Northern hybridizations demonstrated a 3–5-fold increase in both the full-length retroviral message encoding MDR1 and the subgenomic mRNA encoding GST {pi} after amplification of resistance from 60 to 1280 ng/ml colchicine. The cytotoxic effects of several xenobiotics were evaluated in NIH 3T3 cells transfected with MDR1 (3T3.MDR) or transduced with the MDR1-GST {pi} retrovirus (3T3.GST640 or 3T3.GST1280) to evaluate the ability of our vector to produce a spectrum of drug resistances specific for the genes expressed. 3T3.MDR and 3T3.GST1280 cells expressing equivalent levels of MDR1 had identical levels of resistance to doxorubicin or colchicine. These results suggest that GST{pi} expression did not contribute to doxorubicin resistance in this model system. However, 3T3.GST640 cells were about 4-fold resistant to ethacrynic acid and 1-chloro-2,4-dinitrobenzene compared to cells expressing MDR1 alone, consistent with the ability of GST {pi} to conjugate both of these cytotoxins. Increases in drug resistance paralleled increases in gene-specific mRNA and recombinant protein levels in all cases. Thus, our studies suggest that the amplifiable coexpression of MDR1 plus a second potentially therapeutic gene of interest is a feasible strategy for the delivery of multiple drug resistance genes to normal cells for protection against the toxic side effects of combination chemotherapy.

1 Supported by National Cancer Institute Grants CA59308 and CA33572.

2 To whom requests for reprints should be addressed, at Department of Cell and Tumor Biology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010.

Received 5/27/94. Accepted 7/13/95.




This article has been cited by other articles:


Home page
Cancer Res.Home page
F. Chu, P. M. Chou, X. Zheng, B. L. Mirkin, and A. Rebbaa
Control of Multidrug Resistance Gene mdr1 and Cancer Resistance to Chemotherapy by the Longevity Gene sirt1
Cancer Res., November 15, 2005; 65(22): 10183 - 10187.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. Ishii, T. Matsuse, H. Igarashi, M. Masuda, S. Teramoto, and Y. Ouchi
Tobacco smoke reduces viability in human lung fibroblasts: protective effect of glutathione S-transferase P1
Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1189 - L1195.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.